Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Chordia Therapeutics Inc. ( (JP:190A) ) just unveiled an update.
Chordia Therapeutics has formally terminated its license agreement with Ono Pharmaceutical for CTX-177, a MALT1 inhibitor for lymphoid hematologic cancers, following Ono’s earlier strategic decision to halt development and return global rights. Under the agreement, Ono will transfer all clinical and non-clinical data to Chordia at no cost, end its Phase 1 trials in the U.S. and Japan, and allow Chordia to become the sole applicant on related combination-therapy patents, with the biotech expecting minimal impact on its FY2026 results.
With the termination complete, Chordia regains full control of CTX-177 and plans to leverage the inherited data to explore strategic options, including potential resumption of development or re-licensing to new partners. Management emphasizes that CTX-177 still shows strong scientific promise, and consolidating rights and data may strengthen Chordia’s negotiating position in business development while reinforcing its broader oncology pipeline strategy.
The most recent analyst rating on (JP:190A) stock is a Hold with a Yen115.00 price target. To see the full list of analyst forecasts on Chordia Therapeutics Inc. stock, see the JP:190A Stock Forecast page.
More about Chordia Therapeutics Inc.
Chordia Therapeutics Inc. is a Japan-based biotechnology company focused on developing small-molecule oncology drugs, including targeted inhibitors for hematologic and solid tumors. Its lead asset, rogocekib (CLK inhibitor CTX-712), is in a Phase 1/2 trial in the U.S., and the company is also advancing candidates such as MALT1 inhibitor CTX-177, CDK12 inhibitor CTX-439, and GCN2 inhibitors to build a diversified cancer-focused pipeline.
Average Trading Volume: 994,340
Technical Sentiment Signal: Sell
Current Market Cap: Yen8.04B
Find detailed analytics on 190A stock on TipRanks’ Stock Analysis page.